Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Franklin Biotechnology Discovery Fund Class R6 (FRBRX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.


1 month+4.32% 3 years--
3 months-3.17% 5 years--
1 year+8.18% Since inception+28.25%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return--+20.66%
Expense ratio0.60%1.39%
Risk 5 year sharpe ratio1.281.42
Net assets$1.7B$3.8B
Average market cap$8.5B$35.0B
Average P/E21.224.4
Portfolio turnover41%41%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 18 Years
Minimal initial investment$0.00
Minimum IRA investment--


U.S. stock90.07%
International stock4.53%
Fixed income2.38%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
GILD Gilead Sciences9.48%
CELG Celgene8.07%
BIIB Biogen6.64%
AMGN Amgen4.81%
INCY Incyte Corp4.35%
REGN Regeneron Pharmaceuticals3.46%
ILMN Illumina Inc2.90%
BMRN Biomarin Pharmaceutical Inc2.67%
MDVN Medivation Inc2.33%
HRTX Heron Therapeutics Inc2.24%

Partner Offers